Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses.

PubWeight™: 4.04‹?› | Rank: Top 1%

🔗 View Article (PMC 2556874)

Published in Nat Neurosci on March 23, 2008

Authors

Sofia Papadia1, Francesc X Soriano, Frédéric Léveillé, Marc-Andre Martel, Kelly A Dakin, Henrik H Hansen, Angela Kaindl, Marco Sifringer, Jill Fowler, Vanya Stefovska, Grahame McKenzie, Marie Craigon, Roderick Corriveau, Peter Ghazal, Karen Horsburgh, Bruce A Yankner, David J A Wyllie, Chrysanthy Ikonomidou, Giles E Hardingham

Author Affiliations

1: Centre for Neuroscience Research, University of Edinburgh, Hugh Robson Building George Square, Edinburgh EH8 9XD, UK.

Articles citing this

(truncated to the top 100)

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci (2010) 5.27

Protein denitrosylation: enzymatic mechanisms and cellular functions. Nat Rev Mol Cell Biol (2009) 2.42

Cysteine-mediated redox signaling: chemistry, biology, and tools for discovery. Chem Rev (2013) 2.02

The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron (2012) 1.97

Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci (2009) 1.87

Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci (2010) 1.86

Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis (2010) 1.84

Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A (2013) 1.73

Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired neuroprotection induced by synaptic activity. PLoS Genet (2009) 1.72

Stressin' Sestrins take an aging fight. EMBO Mol Med (2010) 1.65

Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience (2011) 1.62

Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci (2008) 1.58

Induction of sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the neuroprotective Nrf2 activator 3H-1,2-dithiole-3-thione. J Neurochem (2008) 1.58

Sestrins orchestrate cellular metabolism to attenuate aging. Cell Metab (2013) 1.58

Aberrant protein s-nitrosylation in neurodegenerative diseases. Neuron (2013) 1.55

Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans (2009) 1.50

Mechanisms of specificity in neuronal activity-regulated gene transcription. Prog Neurobiol (2011) 1.49

Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J (2009) 1.47

Nuclear calcium signalling in the regulation of brain function. Nat Rev Neurosci (2013) 1.44

Suppression of the intrinsic apoptosis pathway by synaptic activity. J Neurosci (2010) 1.40

Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal (2012) 1.36

Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling. Antioxid Redox Signal (2011) 1.29

Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Mol Cells (2009) 1.26

Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death Differ (2011) 1.25

Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem Biophys Res Commun (2009) 1.23

A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther (2010) 1.22

Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning. Proc Natl Acad Sci U S A (2010) 1.22

Synaptic NMDA receptors mediate hypoxic excitotoxic death. J Neurosci (2012) 1.22

Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology (2009) 1.21

Retracted Modulation of ischemia-induced NMDAR1 activation by environmental enrichment decreases oxidative damage. J Neurotrauma (2011) 1.21

Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene. Channels (Austin) (2009) 1.21

Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav (2011) 1.18

Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimer's and Parkinson's diseases. Apoptosis (2010) 1.16

Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration. Cell Death Differ (2012) 1.15

Satb1 is an activity-modulated transcription factor required for the terminal differentiation and connectivity of medial ganglionic eminence-derived cortical interneurons. J Neurosci (2012) 1.14

Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Mol Neurobiol (2010) 1.13

Neuronal activity regulates astrocytic Nrf2 signaling. Proc Natl Acad Sci U S A (2013) 1.13

Distinct roles for μ-calpain and m-calpain in synaptic NMDAR-mediated neuroprotection and extrasynaptic NMDAR-mediated neurodegeneration. J Neurosci (2013) 1.12

Sulfiredoxin Translocation into Mitochondria Plays a Crucial Role in Reducing Hyperoxidized Peroxiredoxin III. J Biol Chem (2009) 1.11

Nuclear factor of activated T-cells isoform c4 (NFATc4/NFAT3) as a mediator of antiapoptotic transcription in NMDA receptor-stimulated cortical neurons. J Neurosci (2009) 1.11

Hepatoprotective role of Sestrin2 against chronic ER stress. Nat Commun (2014) 1.09

State-dependent changes in astrocyte regulation of extrasynaptic NMDA receptor signalling in neurosecretory neurons. J Physiol (2011) 1.08

Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res (2010) 1.08

Reduction of cysteine sulfinic acid in peroxiredoxin by sulfiredoxin proceeds directly through a sulfinic phosphoryl ester intermediate. J Biol Chem (2008) 1.08

Influence of GluN2 subunit identity on NMDA receptor function. Neuropharmacology (2013) 1.07

Opiate drug use and the pathophysiology of neuroAIDS. Curr HIV Res (2012) 1.07

Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology? Schizophr Res (2014) 1.06

Thioredoxin-interacting protein (Txnip) gene expression: sensing oxidative phosphorylation status and glycolytic rate. J Biol Chem (2010) 1.06

Human embryonic stem cell derived astrocytes mediate non-cell-autonomous neuroprotection through endogenous and drug-induced mechanisms. Cell Death Differ (2011) 1.06

Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy. Antioxid Redox Signal (2014) 1.05

Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias. Neurochem Res (2011) 1.04

Session III: Mechanisms of age-related cognitive change and targets for intervention: inflammatory, oxidative, and metabolic processes. J Gerontol A Biol Sci Med Sci (2012) 1.03

The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. J Biol Chem (2014) 1.00

Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies. Cell Calcium (2010) 1.00

S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Antioxid Redox Signal (2011) 1.00

Activation of Nrf2-regulated glutathione pathway genes by ischemic preconditioning. Oxid Med Cell Longev (2011) 0.99

Elevated synaptic activity preconditions neurons against an in vitro model of ischemia. J Biol Chem (2008) 0.99

Sestrins at the crossroad between stress and aging. Aging (Albany NY) (2010) 0.98

Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal cyclooxygenase-2 function, lipid peroxidation, and neuroprotection. J Neurosci (2011) 0.98

Antioxidant activity of sestrin 2 controls neuropathic pain after peripheral nerve injury. Antioxid Redox Signal (2013) 0.98

Mitochondrial thiols in the regulation of cell death pathways. Antioxid Redox Signal (2012) 0.97

Nrf2 target genes can be controlled by neuronal activity in the absence of Nrf2 and astrocytes. Proc Natl Acad Sci U S A (2014) 0.97

Protective effect of carnosic acid, a pro-electrophilic compound, in models of oxidative stress and light-induced retinal degeneration. Invest Ophthalmol Vis Sci (2012) 0.97

Janus-faced Sestrin2 controls ROS and mTOR signalling through two separate functional domains. Nat Commun (2015) 0.96

Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. Nat Commun (2015) 0.96

TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner. Neuropharmacology (2012) 0.96

Linking redox regulation of NMDAR synaptic function to cognitive decline during aging. J Neurosci (2013) 0.96

Tonic NMDA receptor-mediated current in prefrontal cortical pyramidal cells and fast-spiking interneurons. J Neurophysiol (2012) 0.95

Role of histone acetylation in the activity-dependent regulation of sulfiredoxin and sestrin 2. Epigenetics (2009) 0.95

α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum. Adv Exp Med Biol (2012) 0.94

Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci (2016) 0.94

Recent insights into the mode of action of memantine and ketamine. Curr Opin Pharmacol (2014) 0.94

The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry (2014) 0.93

Imbalance of neurotrophin receptor isoforms TrkB-FL/TrkB-T1 induces neuronal death in excitotoxicity. Cell Death Dis (2012) 0.92

Neuronal activity controls the antagonistic balance between peroxisome proliferator-activated receptor-γ coactivator-1α and silencing mediator of retinoic acid and thyroid hormone receptors in regulating antioxidant defenses. Antioxid Redox Signal (2011) 0.92

Toxicity of neurons treated with herbicides and neuroprotection by mitochondria-targeted antioxidant SS31. Int J Environ Res Public Health (2011) 0.92

The influence of synaptic activity on neuronal health. Curr Opin Neurobiol (2011) 0.92

Downregulation of Kv4.2 channels mediated by NR2B-containing NMDA receptors in cultured hippocampal neurons. Neuroscience (2010) 0.92

Redox regulation of lipopolysaccharide-mediated sulfiredoxin induction, which depends on both AP-1 and Nrf2. J Biol Chem (2010) 0.91

Cholesterol loss during glutamate-mediated excitotoxicity. EMBO J (2012) 0.91

Insulin-like growth factor-1 lowers spreading depression susceptibility and reduces oxidative stress. J Neurochem (2012) 0.91

Developmental expression of N-methyl-D-aspartate (NMDA) receptor subunits in human white and gray matter: potential mechanism of increased vulnerability in the immature brain. Cereb Cortex (2013) 0.91

The role of tumor suppressor p53 in the antioxidant defense and metabolism. Subcell Biochem (2014) 0.90

TNF-α and Microglial Hormetic Involvement in Neurological Health & Migraine. Dose Response (2010) 0.90

Developmental localization of NMDA receptors, Src and MAP kinases in mouse brain. Neurosci Lett (2011) 0.89

Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium. Future Neurol (2010) 0.89

Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist. Br J Pharmacol (2012) 0.89

Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus. Nat Commun (2015) 0.89

NMDA receptor activity regulates transcription of antioxidant pathways. Nat Neurosci (2008) 0.89

Moderate ethanol preconditioning of rat brain cultures engenders neuroprotection against dementia-inducing neuroinflammatory proteins: possible signaling mechanisms. Mol Neurobiol (2010) 0.88

Astrocyte NMDA receptors' activity sustains neuronal survival through a Cdk5-Nrf2 pathway. Cell Death Differ (2015) 0.87

Vitamin D3 up-regulated protein 1(VDUP1) is regulated by FOXO3A and miR-17-5p at the transcriptional and post-transcriptional levels, respectively, in senescent fibroblasts. J Biol Chem (2010) 0.87

PGC-1α negatively regulates extrasynaptic NMDAR activity and excitotoxicity. J Neurosci (2012) 0.87

Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1. J Neurochem (2011) 0.87

Thioredoxin binding protein (TBP)-2/Txnip and α-arrestin proteins in cancer and diabetes mellitus. J Clin Biochem Nutr (2011) 0.87

Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2. Nat Commun (2015) 0.86

FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801. BMC Cancer (2013) 0.86

Huntington's Disease and Striatal Signaling. Front Neuroanat (2011) 0.86

Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Neuro Oncol (2014) 0.86

Emerging therapies in traumatic brain injury. Semin Neurol (2015) 0.86

Articles cited by this

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32

Gene regulation and DNA damage in the ageing human brain. Nature (2004) 9.01

Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci (2003) 8.84

Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci (2002) 7.57

Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science (1999) 6.37

Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science (2004) 5.88

Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A (2004) 5.65

Oxidative stress and neurodegeneration: where are we now? J Neurochem (2006) 5.44

ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature (2003) 4.45

The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci (1999) 4.37

FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol (2003) 4.31

NMDA-receptor-mediated, cell-specific integration of new neurons in adult dentate gyrus. Nature (2006) 4.01

NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci (2007) 3.44

Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology (2005) 3.00

Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat Med (1999) 2.78

Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. EMBO J (2000) 2.74

DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. J Biol Chem (1996) 2.38

Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem (2004) 2.35

Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem (2004) 2.32

The high reactivity of peroxiredoxin 2 with H(2)O(2) is not reflected in its reaction with other oxidants and thiol reagents. J Biol Chem (2007) 2.25

Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci (2005) 2.16

The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem (2006) 2.13

Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron (2007) 2.08

C-Terminal truncation of NR2A subunits impairs synaptic but not extrasynaptic localization of NMDA receptors. J Neurosci (2000) 1.95

Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci (2006) 1.94

Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins. J Biol Chem (2004) 1.86

Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.86

Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol (2002) 1.85

S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.73

Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol (2005) 1.71

Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron (2007) 1.65

CREB controls LAP/C/EBP beta transcription. Mol Cell Biol (1997) 1.62

The dichotomy of NMDA receptor signaling. Neuroscientist (2007) 1.61

Reactions of yeast thioredoxin peroxidases I and II with hydrogen peroxide and peroxynitrite: rate constants by competitive kinetics. Free Radic Biol Med (2006) 1.55

Design of a C/EBP-specific, dominant-negative bZIP protein with both inhibitory and gain-of-function properties. J Biol Chem (1996) 1.51

Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int Suppl (2007) 1.37

The involvement of thioredoxin and thioredoxin binding protein-2 on cellular proliferation and aging process. Ann N Y Acad Sci (2005) 1.28

Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J Neurochem (2003) 1.27

Characterization of neural cell types expressing peroxiredoxins in mouse brain. Neurosci Lett (2005) 1.25

Diminished neuronal activity increases neuron-neuron connectivity underlying silent synapse formation and the rapid conversion of silent to functional synapses. J Neurosci (2005) 1.24

Pronounced cell death in the absence of NMDA receptors in the developing somatosensory thalamus. J Neurosci (2004) 1.23

Neural activity and survival in the developing nervous system. Mol Neurobiol (2001) 1.23

Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw. FEBS J (2005) 1.21

Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc Natl Acad Sci U S A (2000) 1.21

Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol Cell Neurosci (2007) 1.19

Peroxiredoxin 2 overexpression protects cortical neuronal cultures from ischemic and oxidative injury but not glutamate excitotoxicity, whereas Cu/Zn superoxide dismutase 1 overexpression protects only against oxidative injury. J Neurosci Res (2007) 1.00

Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, is under-expressed in Down syndrome fetal brains. Cell Mol Life Sci (2003) 0.97

Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol (1990) 0.94

Temporary changes of the AP-1 transcription factor binding activity in the gerbil hippocampus after transient global ischemia, and ischemic tolerance induction. Brain Res (2000) 0.87

Distribution of memantine in brain, liver, and blood of the rat. Arzneimittelforschung (1982) 0.86

Articles by these authors

Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol (2008) 12.96

Gene regulation and DNA damage in the ageing human brain. Nature (2004) 9.01

The Systems Biology Graphical Notation. Nat Biotechnol (2009) 8.53

SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell (2008) 5.76

Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods (2009) 4.76

Astrocytes promote myelination in response to electrical impulses. Neuron (2006) 4.23

Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A (2002) 4.18

Neural mechanisms of ageing and cognitive decline. Nature (2010) 3.59

Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem (2003) 3.45

Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med (2002) 3.31

Anesthesia-induced developmental neuroapoptosis. Does it happen in humans? Anesthesiology (2004) 3.22

Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature (2011) 3.18

High-resolution gene expression profiling for simultaneous kinetic parameter analysis of RNA synthesis and decay. RNA (2008) 3.13

Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles. J Physiol (2005) 2.90

Screening for mammalian neural genes via fluorescence-activated cell sorter purification of neural precursors from Sox1-gfp knock-in mice. Proc Natl Acad Sci U S A (2003) 2.86

Complete genome sequence and lytic phase transcription profile of a Coccolithovirus. Science (2005) 2.86

Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome. Arthritis Rheum (2010) 2.50

Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Ann Neurol (2008) 2.46

Glutamate receptor gating. Crit Rev Neurobiol (2004) 2.31

Evolution of the aging brain transcriptome and synaptic regulation. PLoS One (2008) 2.23

The aging stress response. Mol Cell (2010) 2.19

Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci (2005) 2.16

Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A (2012) 2.14

Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 2.10

The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. Biochem J (2006) 2.03

Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci (2003) 2.01

The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron (2012) 1.97

The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity (2012) 1.96

Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci (2006) 1.94

Ethanol-induced apoptotic neurodegeneration in the developing C57BL/6 mouse brain. Brain Res Dev Brain Res (2002) 1.89

Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron (2002) 1.82

Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6. Diabetes (2005) 1.77

Transcriptome profile of murine gammaherpesvirus-68 lytic infection. J Gen Virol (2003) 1.75

SPRINT: a new parallel framework for R. BMC Bioinformatics (2008) 1.75

Do pediatric drugs cause developing neurons to commit suicide? Trends Pharmacol Sci (2004) 1.67

Genome-wide expression profiling of in vivo-derived bloodstream parasite stages and dynamic analysis of mRNA alterations during synchronous differentiation in Trypanosoma brucei. BMC Genomics (2009) 1.67

The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet (2005) 1.66

The dichotomy of NMDA receptor signaling. Neuroscientist (2007) 1.61

Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission. Mol Pharmacol (2006) 1.59

Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci (2008) 1.58

Induction of sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the neuroprotective Nrf2 activator 3H-1,2-dithiole-3-thione. J Neurochem (2008) 1.58

Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol (2007) 1.56

Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol (2011) 1.56

Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol (2005) 1.51

Therapeutic doses of topiramate are not toxic to the developing rat brain. Exp Neurol (2004) 1.49

A logic-based diagram of signalling pathways central to macrophage activation. BMC Syst Biol (2008) 1.49

A RIP tide in neuronal signal transduction. Neuron (2002) 1.48

Homeostasis of intrinsic excitability in hippocampal neurones: dynamics and mechanism of the response to chronic depolarization. J Physiol (2009) 1.41

Suppression of the intrinsic apoptosis pathway by synaptic activity. J Neurosci (2010) 1.40

Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans. J Neurosci (2010) 1.39

Discrete clusters of virus-encoded micrornas are associated with complementary strands of the genome and the 7.2-kilobase stable intron in murine cytomegalovirus. J Virol (2007) 1.39

Interleukin Converting Enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production. Neurobiol Dis (2008) 1.39

High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J Gen Virol (2009) 1.34

PEDRo: a database for storing, searching and disseminating experimental proteomics data. BMC Genomics (2004) 1.34

Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol (2010) 1.33

Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J Neurosci (2005) 1.33

Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol (2009) 1.31

Transcriptomal analysis of varicella-zoster virus infection using long oligonucleotide-based microarrays. J Gen Virol (2005) 1.31

NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci U S A (2005) 1.30

Mitochondrial calcium uniporter Mcu controls excitotoxicity and is transcriptionally repressed by neuroprotective nuclear calcium signals. Nat Commun (2013) 1.30

Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol Dis (2004) 1.30

Pharmacological insights obtained from structure-function studies of ionotropic glutamate receptors. Br J Pharmacol (2006) 1.29

Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des (2010) 1.27

Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Mol Cells (2009) 1.26

Activin/Nodal inhibition alone accelerates highly efficient neural conversion from human embryonic stem cells and imposes a caudal positional identity. PLoS One (2009) 1.24

Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol (2007) 1.24

Erythropoietin protects the developing brain against N-methyl-D-aspartate receptor antagonist neurotoxicity. Neurobiol Dis (2004) 1.23

Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning. Proc Natl Acad Sci U S A (2010) 1.22

Nuclear Ca2+ and CaM kinase IV specify hormonal- and Notch-responsiveness. J Neurochem (2005) 1.22

Compartmentalized NMDA receptor signalling to survival and death. J Physiol (2007) 1.21

Neutrality of the canonical NF-kappaB-dependent pathway for human and murine cytomegalovirus transcription and replication in vitro. J Virol (2004) 1.21

Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene. Channels (Austin) (2009) 1.21

Neuroprotection after transient global cerebral ischemia in Wld(s) mutant mice. J Cereb Blood Flow Metab (2004) 1.20

Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol (2005) 1.20